Does Cardarine Actually Cause Cancer?

Cardarine sits in a strange place in the performance enhancement world, where the people defending it and the people condemning it are both working from incomplete information, and the truth requires understanding what the drug actually does before you can evaluate what the studies actually show.

Start with the mechanism. Inside your cells there are receptors that act like switches, binding to certain molecules and then turning specific genes on or off. Cardarine activates something called PPARdelta, which is a receptor that controls genes involved in fat oxidation and mitochondrial development. When PPARdelta gets activated, your body shifts toward burning fat for fuel, builds more mitochondria, and increases endurance capacity. That is the whole appeal of the compound. It essentially mimics some of the adaptations that come from aerobic training, which is why it was originally developed and why athletes became interested in it.

Now you can understand what the cancer concern is actually about.

GlaxoSmithKline ran the two-year carcinogenicity studies that are standard for drug development, one in rats and one in mice. Two years in a rat spans essentially its entire adult life, which using standard lifespan scaling translates to roughly 60 years of daily human exposure. In both species, they found tumors across multiple organ systems, including the liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. The finding that mattered most was not the presence of tumors at high doses, because high doses of almost anything cause problems. What mattered was that tumors appeared at every dose level they tested, including the lowest. They never found a threshold below which the signal went away. That is what stopped the drug from ever reaching market.

The most common response to this in fitness communities is that the doses used were far above anything a human would take, and that response is partially correct and partially misleading.

Using the FDA-preferred conversion method, which adjusts for differences in body surface area between species rather than just raw milligrams per kilogram, the lowest dose that produced tumors in female rats translates to roughly 39 milligrams per day for a 175-pound person. For males it comes out closer to 64 milligrams per day. Most people using cardarine are taking somewhere between 10 and 20 milligrams. So yes, there is a gap between the doses in the studies and the doses people actually use.

But that gap is only about two to six times, and pharmaceutical development sets a minimum safety margin of ten times before a compound is considered safe to proceed. And that standard exists even when researchers can find a no-effect dose. In the cardarine studies, they never found one.

There is also something worth understanding about how PPARdelta behaves in the body during exercise versus during pharmacological activation, because this is where the mechanism gets more specific and where the AMPK connection becomes relevant.

When you exercise, PPARdelta gets activated as part of the metabolic response, and your body gets the fat-burning and mitochondrial benefits people associate with cardarine. But exercise simultaneously activates something called AMPK, which is a separate energy-sensing enzyme that functions like a molecular brake on certain downstream effects of PPARdelta. Research published in the Journal of Biological Chemistry in 2021 showed that AMPK phosphorylates PPARdelta at a specific site called serine 50, and that this modification suppresses the pro-tumorigenic transcriptional programs while preserving the metabolic ones. In plain terms, exercise turns on the receptor but also turns on a check that limits the cancer-promoting side of its activity.

Cardarine activates PPARdelta without necessarily engaging that same AMPK-mediated check. The receptor gets turned on, but the brake does not automatically come with it.

This does not mean cardarine will give you cancer. It means the mechanism by which exercise safely activates this receptor involves a co-regulatory pathway that a drug alone may not replicate, and that distinction matters when you are trying to interpret what the animal studies show.

The only human trial that exists involved 268 subjects taking up to 10 milligrams per day for 12 weeks, and it found no serious adverse events. What that study tells you is limited, because 12 weeks is nowhere near long enough to assess cancer risk, and cancer as an endpoint was never the study's purpose. It tells you roughly that short-term use at that dose does not cause immediate obvious harm. That is about the extent of what you can conclude from it.

So the honest accounting of the evidence looks like this. Two species, same multi-organ tumor signal, at every dose tested, over a lifetime of exposure. A safety margin between human-use doses and tumor-producing doses that falls below what pharmaceutical development considers acceptable. A mechanistic reason to believe that exercise and pharmacological activation of PPARdelta may not be equivalent even when the receptor is the same. And zero long-term human data on cancer endpoints at the doses people actually use.

That last piece is not going to be filled in. No ethics board would approve a study designed to test whether a compound causes cancer in healthy humans over years of use, and no company has financial incentive to fund it given that the drug never made it to market.

What that leaves you with is a decision made inside a data gap. The people saying it definitely causes cancer are extrapolating from animal data at doses above typical human use. The people saying it is definitely safe are pointing to the absence of human evidence, which is not the same thing as evidence of absence. Both groups are filling in the unknown with a conclusion they prefer.

The compound activates a receptor that, in animal studies across two species, produced tumors at every dose level tested, without the co-regulatory brake that exercise naturally engages. The size of the gap between those doses and human-use doses is real but not as large as the rhetoric suggests, and the absence of a safe threshold in the animal data is not a detail you can dismiss by pointing at dose conversion alone.

That is the actual picture. What you do with it is your decision, but you should make it knowing what the picture contains.

---

References

1. Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ 2009. Rat two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting, Abstract #895. Multi-organ tumors at all dose levels in Han Wistar rats including liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. Source
2. Newsholme SJ, Dunsford WS, et al. 2009. Mouse two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting. Multi-organ tumor signal confirmed in mice, consistent with rat findings. Source
3. Ding Y, et al. 2021. AMPK phosphorylates PPARdelta at Serine 50, suppressing pro-tumorigenic transcriptional programs while preserving metabolic benefits. Journal of Biological Chemistry, 297:100954. Source
4. Reagan-Shaw S, Nihal M, Ahmad N 2008. Dose translation from animal to human studies revisited. FASEB Journal, 223:659-661. FDA-preferred body surface area normalization method for interspecies dose conversion. Source
5. Olson EJ, Pearce GL, Jones NP, Sprecher DL 2012. Human RCT, 268 subjects, up to 10 mg/day for 12 weeks. No serious adverse events but far too short for cancer assessment. Arteriosclerosis, Thrombosis, and Vascular Biology, 329:2289-2294. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness